ESC糖尿病合并心血管疾病管理指南解读

详细信息

收稿日期: 2023-09-10

刊出日期: 2023-10-13

Interpretation to 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes

- Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

More Information

Received Date: 10 September 2023

Publish Date: 13 October 2023

摘要: 《2023 ESC糖尿病合并心血管疾病管理指南》在2023年8月举行的欧洲心脏病学年会(ESC 2023)上重磅发布。该指南重视心血管病(CVD)、慢性肾病(CKD)与糖尿病(DM)之间的相互影响，以SGLT2i作为有力抓手，做到“心肾共治”，强调“以改善心肾结局为目标”的治疗理念。
- 糖尿病 /
- 心血管疾病 /
- ESC指南更新
Abstract: 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes were released at the European Society of Cardiology congress in August 2023. The guild line pay attention to the interaction between cardiovascular disease, chronic kidney disease and diabetes mellitus. Using SGLT2i as a powerful starting point to achieve cardio-renal co-treatment and emphasize the treatment concept of aiming to improve cardiovascular and renal outcomes.
- cardiovascular disease /
- diabetes /
- ESC guideline update

图 1 T2DM合并CVD患者的管理：临床方法和主要建议

Figure 1. Management of patients with T2DM combined with CVD

下载: 全尺寸图片幻灯片

图 2 T2DM患者的心血管风险评估

Figure 2. Cardiovascular risk assessment in patients with T2DM

下载: 全尺寸图片幻灯片

图 3 T2DM合并ASCVD患者的降糖治疗

Figure 3. Hypoglycemic therapy in patients with T2DM combined with ASCVD

下载: 全尺寸图片幻灯片

图 4 T2DM合并HF患者的降糖治疗

Figure 4. Hypoglycemic therapy in T2DM with HF

下载: 全尺寸图片幻灯片

图 5 降低T2DM合并CKD患者心血管或肾衰竭风险的药物治疗

Figure 5. Pharmacological therapy to reduce the risk of cardiovascular or renal failure in patients with T2DM and CKD

下载: 全尺寸图片幻灯片

[1]	Marx N, Federici M, Schutt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes[J]. Eur Heart J, 2023, doi: 10.1093/eurheartj/ehad192.